Executives working for Elon Musk have been advised not to seek a higher security clearance for him due to concerns about his drug use and contact with foreign nationals, according to reports.

According to the report, Musk has been violating the rules set out by his "top secret" security clearance for years. Musk was even denied high-level security access by the Air Force, according to ...

Musk has reportedly failed to cooperate with security clearance reporting rules, hiding info on things like meetings with foreign leaders. According to disclosure stipulations, Musk is required to ...

Teva Pharmaceuticals’TEVA0.63%increase; green up pointing triangle shares soared and Sanofi’sSAN-0.33%decrease; red down pointing triangle stock moved higher following positive results from ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those taking placebo treatment. Teva announced it was partnering with Sanofi to ...

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC ...

ADRs of Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) traded higher in the premarket on Tuesday after the companies said that their experimental antibody therapy, duvakitug, reached the ...

Merck is working on the monoclonal antibody MK-7240—formerly known as PRA023—which it acquired in its $10.8 billion buyout of Prometheus Biosciences last year. In phase 2 results disclosed in ...

Teva Pharmaceuticals' shares soared and Sanofi's stock moved higher following positive results from the latest trial of their jointly developed treatment for inflammatory bowel disease. The ...

17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they would collaborate on developing a ...

Duvakitug isn't just another drug in Teva's pipelineit's the drug. With consistent efficacy across patient groups and no major safety hiccups, this TL1A antibody therapy is now a frontrunner in ...

A Teva Pharmaceuticals drug being developed in partnership with Sanofi to hit a promising but competitive target for inflammation now has positive data from a clinical test in the two most common ...